NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the E ...

In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, ...

Moderna on Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the marketing authorization of mNexspike, a new Covid-19 vaccine. The committee's ...

Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion ...

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug ...

Moderna Inc. (NASDAQ: MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

NEW YORK, NY / ACCESS Newswire / December 15, 2025 / As the market has paid increasing attention to, and begun revaluing, SMX's potential across plastics, gold, rare earths, and hardware ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...